PDS Biotechnology Corporation
NASDAQ:PDSB
3.28 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | PDS Biotechnology Corporation |
Symbool | PDSB |
Munteenheid | USD |
Prijs | 3.28 |
Beurswaarde | 120,768,944 |
Dividendpercentage | 0% |
52-weken bereik | 2.53 - 6.85 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Frank K. Bedu-Addo Ph.D. |
Website | https://www.pdsbiotech.com |
An error occurred while fetching data.
Over PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)